Navigation Links
Vectibix® (Panitumumab) Granted Approval for Expanded Indications in the European Union
Date:11/15/2011

ement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. FDA, European Medicines Agency (EMA) or similar regulatory bodies for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA, EMA or similar regulatory bodies can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the approved labeling for the products, and not the information discussed in this news release.

(1) Jemal. Global Cancer Statistics. CA CANCER J CLIN 2011;61:69–90

(2) Douillard, JE et al. Randomized, Phase 3 Study (PRIME) of Panitumumab with FOLFOX4 versus FOLFOX4 Alone as First-Line Treatment in Patients With Previ
'/>"/>

SOURCE Amgen Europe GmbH
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
4. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
5. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
6. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
7. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
8. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
9. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
10. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
11. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Research and Markets ... Diagnostic Devices Market 2014-2018" report to their offering. ... About Ophthalmic Diagnostic Device An ophthalmic ... a defect or deficiency in the human visual pathway. ... such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and ...
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. ... provide a corporate update and report second quarter 2014 ... on Friday, August 1, 2014. That same day, Arena ... a.m. Eastern Time (5:30 a.m. Pacific Time). ... 877.643.7155 for domestic callers and 914.495.8552 for international callers. ...
Breaking Medicine Technology:Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... 10, 2011 Sildenafil, a drug used to ... possible use -- helping children and young adults ... Sildenafil significantly improved measures of exercise performance during ... according to researchers from The Children,s Hospital of ...
... seek ways to reduce Medicaid spending, they should start by ... model to the more efficient model used in some parts ... finds that the program could save $473 million over ... more like those in Medicare and commercial plans. Governors Chris ...
Cached Medicine Technology:Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction 2Exercise Performance in Children and Young Adults with Single Ventricle Heart Disease Improves with Use of Drug for Erectile Dysfunction 3Budget Solution? Modernizing Medicaid Pharmacy Could Save Florida $473 Million 2
(Date:7/26/2014)... July 26, 2014 As the ... the true vision of Xoçai is ... its exclusive and healthy chocolate products. One such ... of cacao, açaí berries and blueberries, an ingredient ... high-antioxidant blend is utilized in all of Xoçai ...
(Date:7/25/2014)... Dental Perfection, a Derby cosmetic dentist ... general dentistry, clear braces and much more, has just ... in Derby. The new practice, which is scheduled to ... in Littleover, Derby. Patients may already pre-register for the ... dental practice, which is headed by Invisalign specialist and ...
(Date:7/25/2014)... Dallas, Texas (PRWEB) July 26, 2014 ... Global and China Gel Permeation Chromatography Industry” ... on the Global and China Gel Permeation ... Permeation Chromatography information, including Gel Permeation Chromatography ... as well as industry overview. This research ...
(Date:7/25/2014)... July 25, 2014 In recent years, men ... eager to reverse the symptoms associated with age-related testosterone decline. ... at large, a new case study from Renew ... of testosterone therapy using bioidentical hormones. , The case ... from Seattle who found himself beginning to feel the effects ...
(Date:7/25/2014)... American motor vehicle owners who are at higher ... premiums for vehicle insurance on average. The Quotes Pros ... SR22 insurance for high risk motorists this year at ... of local agencies providing direct price quotations for risk ... available for any car owner to access. One advantage ...
Breaking Medicine News(10 mins):Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:SR22 Insurance for High Risk Motorists Added to Local Quotes System at Insurer Website Online 2
... , , , ... Costs Will Increase , , ... Director Douglass Elmendorf about current legislative drafts proposed by the Senate and ... care costs in the U.S. -- chronic disease. , ...
... the treatment of disease ,The team, led ... Research at the University of Copenhagen and the Max Planck ... in 1,750 different proteins. "This is more than ... of known acetylation switches by a factor of six, and ...
... prevention, treatment and care throughout Europe by improving communications within ... the launch of a new website: www.eurocancercoms.eu . The ... from researchers and doctors to patients. The ... Oncology and is led by ECCO the European CanCer ...
... only four sites across the country to participate in a ... investigate the effectiveness of a chemotherapeutic agent, ThermoDox, used in ... treating recurrent chest wall breast cancer. Recurrent chest ... on the chest wall, most commonly presenting in the skin ...
... are diagnosed with pancreatic cancer. Few live very long, ... after diagnosis. There,s new hope, though, from the ... University,s Faculty of Life Sciences. His drug compound Salirasib ... passed Phase I/II clinical trials. The drug, given in ...
... at Ben-Gurion University of the Negev (BGU) have conducted a ... adolescents, demonstrating that strong social support from friends is a ... to be the first of its type, was published in ... The American Academy of Pediatrics. ...
Cached Medicine News:Health News:PFCD Urges Congress to Address Real Cost-Driver in Health Reform in Light of New CBO Statement 2Health News:New Web site launches $1.7 million project to improve European cancer communications 2Health News:New Web site launches $1.7 million project to improve European cancer communications 3Health News:RI Hospital first in country to enroll patient in new study for recurrent chest wall breast cancer 2Health News:New drug candidate prolongs the lives of pancreatic cancer patients 2Health News:Social support buffers adolescent depression after terrorist attacks: Ben-Gurion University 2
PDA format of the well-known standard antimicrobial reference....
PDA application providing a complete guide for the diagnosis and management of electrolyte disorders....
Contains the most common procedures from all orthopedic sub-specialties organized by body area....
Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
Medicine Products: